QNCX earnings analysis
What we found in QNCX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Quince remains a pre-commercial clinical-stage biopharmaceutical company with $0 revenue and a reported diluted EPS of -$12.31 for the quarter. Six-month net loss increased to $39.6 million from $31.1 million, while accumulated deficit reached $500.0 million; the company also recorded a $67.8 million intangible-asset impairment tied to the NEAT study. The Orphai acquisition and July 2026 PH-ILD Phase 2b start advance the LAM-001 program, but continued losses, dependence on additional financing, integration execution and regulatory approval requirements remain substantial risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- LAM-001 Clinical Development Advanced
- The company initiated a Phase 2b clinical trial of LAM-001 in PH-ILD in July 2026 and expects to initiate a Phase 2 SAPH trial in late 2026.
- Orphai Acquisition Completed
- Quince completed the Orphai acquisition on May 18, 2026, expanding its pipeline around LAM-001 and serious pulmonary disorders.
- ATM Financing Added Liquidity
- The company raised approximately $20.3 million of net proceeds through its ATM program during the six months ended June 30, 2026, issuing 526,435 common shares.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent Losses and No Revenue
- The company reported a net loss of $39.6 million for the six months ended June 30, 2026, versus $31.1 million in the prior-year period, and its accumulated deficit reached $500.0 million as of June 30, 2026. It has no approved products and has not generated commercial product revenue.
- Material Intangible-Asset Impairment
- The company recognized a total impairment charge of $67.8 million for indefinite- and finite-lived intangible assets for the six months ended June 30, 2026, related to the negative outcome of the NEAT study, highlighting material pipeline and acquisition-asset impairment risk.
- Acquisition Integration and Financing Risk
- Post-acquisition integration is expected to continue through the remainder of 2026, including integration of Orphai’s financial processes, systems and personnel. Failure to obtain required approvals could also force cash settlement of Series C Preferred Stock; the company increased its authorized-share proposal from 250.0 million to 275.0 million shares.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-12.31
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing. Management states it expects significant expenses and increasing operating losses for the foreseeable future, and expects SAPH Phase 2 initiation in late 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- Quince Therapeutics reported another significant loss in Q4 2026, with revenue remaining undisclosed. Their diluted EPS deteriorated further to -0.76, a notable miss against the -0.21 consensus estimate. The company has…
- 10-K · April 10, 2026
- Quince completed its pivotal NEAT Phase 3 trial in January 2026 but the trial did not meet the primary endpoint (mean change 0.94 active vs 2.24 placebo; difference -1.30; p=0.0851), and management states eDSP "does not…
- 10-Q · August 11, 2025
- Quince reported a net loss of $16,049 (three months ended June 30, 2025) versus $27,729 in the prior-year quarter, with GAAP EPS of $(0.34) (vs $(0.64) a year ago) but missing the consensus estimate of $(0.25). Cash and…
- 10-Q · May 13, 2025
- Quince Therapeutics reported a quarterly net loss of $15,030,000 (‑$0.34 per share) for the three months ended March 31, 2025, driven by a sharp R&D ramp to $8,145,000 and a $1,924,000 fair value adjustment to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing QNCX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever